U.S. markets closed
  • S&P 500

    3,666.72
    -2.29 (-0.06%)
     
  • Dow 30

    29,969.52
    +85.73 (+0.29%)
     
  • Nasdaq

    12,377.18
    +27.82 (+0.23%)
     
  • Russell 2000

    1,848.70
    +10.67 (+0.58%)
     
  • Crude Oil

    45.91
    +0.27 (+0.59%)
     
  • Gold

    1,845.40
    +4.30 (+0.23%)
     
  • Silver

    24.22
    +0.08 (+0.34%)
     
  • EUR/USD

    1.2154
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    0.9200
    -0.0280 (-2.95%)
     
  • GBP/USD

    1.3462
    +0.0009 (+0.07%)
     
  • USD/JPY

    103.7920
    -0.0680 (-0.07%)
     
  • BTC-USD

    19,511.40
    +59.90 (+0.31%)
     
  • CMC Crypto 200

    383.76
    +9.36 (+2.50%)
     
  • FTSE 100

    6,490.27
    +26.88 (+0.42%)
     
  • Nikkei 225

    26,771.11
    -38.26 (-0.14%)
     

The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, Target, Prudential Financial and Seagate Technology

Zacks Equity Research
·4 min read

For Immediate Release

Chicago, IL – October 16, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson JNJ, Pfizer Inc. PFE, Target Corporation TGT, Prudential Financial, Inc. PRU and Seagate Technology plc STX.

Here are highlights from Thursday’s Analyst Blog:

Top Analyst Reports for J&J, Pfizer and Target

The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Pfizer and Target. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Johnson & Johnson have declined -1.0% over the past six months against the Zacks Large Cap Pharmaceuticals industry’s rise of +1.9%. The Zacks analyst believes that the coronavirus pandemic is hurting the company’s Medical Devices unit due to decline in elective surgical procedures and redeployment of hospital resources to address patients affected by the coronavirus pandemic.

J&J also faces a slew of lawsuits, which allege personal injuries to patients caused by the use of its medicines, mainly its talc and opioid products. These lawsuits have resulted in uncertainty.

However, successful label expansion of blockbuster drugs, Imbruvica, Darzalex and Stelara is a major positive. J&J is also making rapid progress with its pipeline and line extensions. (You can read the full research report on Johnson & Johnson here >>>)

Pfizer shares have fallen -5.9% in the year to date period against the Zacks Large Cap Pharmaceuticals industry’s decline of -0.8%. The Zacks analyst believes that busines disruption from coronavirus, currency headwinds and pricing pressure are top-line headwinds for Pfizer. The company’s estimate movement is mixed ahead of Q3 earnings. Pfizer has a mixed record of earnings surprises in the recent quarters.

However, the Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. The smaller Pfizer should see better revenue growth as the Lyrica loss of exclusivity (LOE) cliff will go away.

(You can read the full research report on Pfizer here >>>)

Target shares have outperformed the Zacks Retail - Discount Stores industry over the past one-year period (+46.1% vs. +16.8%). The Zacks analyst believes that the company has been deploying resources to enhance omni-channel capabilities, come up with new brands, refurbish stores and expand same-day delivery options to provide seamless shopping experience. Markedly, the company has been making multiple changes to its business model to adapt and stay relevant in the ever-evolving retail landscape.

Target’s impressive second-quarter fiscal 2020 performance is the testimony of the same, wherein both the top and the bottom lines grew year over year. Notably, comparable sales rose for the 13th straight quarter, gaining from strength in the digital channel as consumers shift to online shopping amid coronavirus-led social distancing.

(You can read the full research report on Target here >>>)

Other noteworthy reports we are featuring today include Prudential Financial and Seagate Technology.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Click to get this free report Johnson Johnson (JNJ) : Free Stock Analysis Report Target Corporation (TGT) : Free Stock Analysis Report Seagate Technology PLC (STX) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Prudential Financial, Inc. (PRU) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research